CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc. Deutsche Boerse AG

Stocks

RV6

US1598641074

Biotechnology & Medical Research

Real-time Estimate Tradegate 16:06:55 02/10/2026 BST			5-day change	1st Jan Change
255.05 ^EUR	-2.39%		-1.28%	+48.27%

09-30	UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175	MT
09-29	PMGC Unit Working With Charles River Laboratories for Muscle Health Probiotic Testing	MT

All News

Mentions Relevance

09-30	UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175	MT
09-28	Jefferies Adjusts PT on Charles River Laboratories International to $340 From $305, Maintains Buy Rating	MT
09-25	Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says	MT
09-25	Deutsche Bank Raises Price Target on Charles River Laboratories International to $320 From $300, Keeps Buy Rating	MT
09-25	RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating	MT
09-25	Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating	MT
09-25	Mizuho Adjusts PT on Charles River Laboratories International to $295 From $264, Keeps Neutral Rating	MT
09-25	Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating	MT
09-25	TD Cowen Adjusts PT on Charles River Laboratories International to $325 From $300, Maintains Buy Rating	MT
09-25	Baird Adjusts PT on Charles River Laboratories International to $334 From $291, Keeps Outperform Rating	MT
09-24	Charles River Laboratories International, Inc. - Analyst/Investor Day
09-24	Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections	MT
09-24	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS at Upper End of $11.15 - $11.45, vs. FactSet Est of $11.33	MT
09-24	Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day	BU
09-17	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
09-17	Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating	MT
09-17	Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines	BU
09-16	Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says	MT
09-15	Charles River Laboratories International, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 09:40 AM
09-14	Charles River Laboratories International, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM
09-11	Charles River Laboratories to Present at Morgan Stanley and Baird Conferences	BU
09-11	Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating	MT
09-09	Charles River Modernizes Endosafe(R) Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite	AQ
09-08	Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite	CI
09-08	Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite	BU